Shionogi’s Mulpleta (lusutrombopag) Receives FDA Approval for Chronic Liver Patients in Adults

 Shionogi’s Mulpleta (lusutrombopag) Receives FDA Approval for Chronic Liver Patients in Adults

Shionogi’s Mulpleta (lusutrombopag) Receives FDA Approval for Chronic Liver Patients in Adults

Shots:
  • Mulpleta is approved based on two randomized, placebo-controlled trials (L-PLUS 1 & 2) involving 312 patients with platelets ≤50 x 109/L randomized 1:1 to receive 3mg once upto 7 days
  •  Oral recommendation is 3mg Q.D. with or without food for 7 days
  •  Results (Mulpleta vs PBO): In L-PLUS 1, No platelet transfusion (78% vs 13%) prior procedure; In L-PLUS 2, No platelet transfusion (65% vs 29%) prior procedure with common AE as headache
Click here to read full press release/ article | Ref: US FDA | Image: Forbes

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post